CDT Equity Inc. (CDT) · Nov 4, 2026 · Rights change
1-for-20 reverse split — 20,357,283 shares reduced to approximately 1,017,864
CDT Equity’s latest reverse split cuts shares 20-for-1, reinforcing a recurring Nasdaq-compliance and financing problem rather than changing the business.
CDT is a clinical-stage, data-driven biotech that is also building a broader platform around strategic partnerships and digital-asset investments, while relying heavily on outside capital before it has commercialized a product.
This filing is another capital-markets repair action, not business progress. CDT is implementing a 1-for-20 reverse split effective November 5, with split-adjusted trading scheduled for November 6. 〔0〕
The scale is meaningful because this is a repeated pattern. The company had already completed five reverse splits through July 2026, then carried out another 1-for-25 split in September; this new action therefore looks less like a one-time housekeeping measure and more like continuing pressure to preserve its Nasdaq listing and keep financing capacity open. The filing itself does not state a new Nasdaq deficiency, so the listing rationale is an inference from the sequence and prior compliance disclosures.
The split does not create value or solve dilution. It combines every 20 shares into one and reduces the outstanding count from 20,357,283 to approximately 1,017,864, but the filing says the par value and other common-stock terms are unchanged. 〔1〕 〔2〕
The surprise is the recurrence, not the mechanics. Stockholders had already authorized future reverse splits, and CDT has used that authority repeatedly; the exact 1-for-20 ratio and timing are new, but the market-facing problem—maintaining a tradable Nasdaq share price—was already well established. This makes the event partly known and negative for the operating story, even though it is not itself a cash-raising transaction.
Bottom line: CDT remains focused on keeping its public-market structure intact while its underlying biotech and investment strategy develops. Another large reverse split does not advance that strategy; it signals that the company is still managing ongoing listing and financing pressure.
Split-adjusted trading begins November 6, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!